Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

Paralog Dependency May Be Exploitable in Tumors Lacking Chromosome 1p

DOI: 10.1158/2159-8290.CD-RW2018-112 Published August 2018
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Cells with chromosome 1p loss and hemizygous deletion of MAGOH are dependent on its paralog, MAGOHB.

  • Mechanism: Inhibition of MAGOHB disrupts alternative splicing and RNA surveillance in MAGOH-deficient cells.

  • Impact: Direct or indirect MAGOHB inhibition may have activity in a wide range of cancers with chromosome 1p deletion.

An emerging concept borne out of synthetic lethality screens is that inactivation of particular genes can confer dependency on their functionally redundant paralogs. Viswanathan and colleagues analyzed such dependencies in genome-wide shRNA and CRISPR synthetic lethal screen datasets and identified the paralogs MAGOH and MAGOHB as genes for which dependency was significantly correlated with inactivation of its paralog. Of note, MAGOH is located on chromosome 1p, which is commonly deleted in human tumors, and hemizygous MAGOH loss occurs in 21% of all tumors cataloged in The Cancer Genome Atlas. MAGOHB was the top dependency in cells with hemizygous MAGOH loss, and chromosome 1p deletion status correlated with MAGOHB dependency. MAGOH and MAGOHB encode core components of the exon–junction complex, a multisubunit complex that acts at exon–exon junctions during splicing and facilitates targeting of transcripts with premature termination codons for nonsense-mediated decay (NMD). In MAGOH-deleted cells, decreased viability upon MAGOHB knockdown was associated with increased intron retention and expression of transcripts that typically would undergo NMD. MAGOHB does not have domains that are obviously amenable to targeting by small molecules, but delivery of MAGOHB siRNA with tumor-penetrating nanocomplexes suppressed growth of tumors with hemizygous deletion of MAGOH. A search for potentially more tractable dependencies that correlated with either MAGOH or MAGOHB dependency identified IPO13, a gene also located on chromosome 1p that encodes the karyopherin responsible for importing MAGOH and MAGOHB to the nucleus, as the top correlated gene dependency to both MAGOH and MAGOHB. Delivery of IPO13 siRNA also suppressed growth of tumors with hemizygous deletion of MAGOH, suggesting that indirect inhibition of MAGOHB may also be effective in the setting of MAGOH loss. Overall, these findings raise the possibility that MAGOH–MAGOHB paralog lethality and the MAGOHB–IPO13 axis may be exploitable vulnerabilities in a substantial subset of human tumors.

Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 2018;50:937–43.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 8 (8)
August 2018
Volume 8, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Paralog Dependency May Be Exploitable in Tumors Lacking Chromosome 1p
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Paralog Dependency May Be Exploitable in Tumors Lacking Chromosome 1p
Cancer Discov August 1 2018 (8) (8) 909; DOI: 10.1158/2159-8290.CD-RW2018-112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Paralog Dependency May Be Exploitable in Tumors Lacking Chromosome 1p
Cancer Discov August 1 2018 (8) (8) 909; DOI: 10.1158/2159-8290.CD-RW2018-112
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Genomics

  • Hürthle Cell Carcinomas Exhibit Widespread Loss of Heterozygosity
  • Error-Prone DNA Repair Targets the H3K36me3 Chromatin of Active Genes
Show more Genomics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement